title: CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma.
abstract: BACKGROUND
  Cancer stem cells (CSCs) are responsible for treatment failure. However, their identification and roles in resistance are not well established in head and neck squamous cell carcinoma (HNSCC).
  
  
  METHODS
  Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation. Cell surface antigens were analysed by LyoPlate, a novel cell surface antigen array. The expression levels of antigens highly expressed after treatments were further compared between cisplatin-resistant Detroit562 cells and its parental line. Association of the candidate antigen with CSCs properties, namely sphere formation and in vivo tumourigenicity, was also examined.
  
  
  RESULTS
  CD10, CD15s, CD146 and CD282 were upregulated across the treated cell lines, while the increased expression of CD10 was prominent in the cisplatin-resistant cell line. Isolation mediated by FACS revealed that the CD10-positive subpopulation was more refractory to cisplatin, fluorouracil and radiation than the CD10-negative subpopulation. It also showed an increased ability to form spheres in vitro and tumours in vivo. Moreover, the CD10-positive subpopulation expressed the CSC marker OCT3/4 at a higher level than that in the CD10-negative subpopulation.
  
  
  CONCLUSIONS
  CD10 is associated with therapeutic resistance and CSC-like properties of HNSCC. CD10 may serve as a target molecule in the treatment of refractory HNSCC.
authors.affiliation: 1] Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan [2] Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Fukusumi
authors.affiliation: Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ishii
authors.affiliation: Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Konno
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yasui
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nakahara
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Takenaka
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
authors.affiliation: Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nishikawa
authors.affiliation: Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kano
authors.affiliation: Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ogawa
authors.affiliation: Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Hasegawa
authors.affiliation: Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Hamabe
authors.affiliation: Department of Surgery, Osaka National Hospital, Osaka, Tyuou-ku, 2-1-14 Houenzaka, Osaka 540-0006, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Haraguchi
authors.affiliation: Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Doki
authors.affiliation: Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University, Graduate School of Medicine, Suita, 2-2 Yamadaoka, Osaka 565-0871, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Inohara
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D059585:G1 Phase Cell Cycle Checkpoints; D015972:Gene Expression Regulation, Neoplastic; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects; D015260:Neprilysin / Q000378:metabolism*; D050814:Octamer Transcription Factor-3 / Q000235:genetics / Q000378:metabolism; D011836:Radiation Tolerance; D000077195:Squamous Cell Carcinoma of Head and Neck; D015854:Up-Regulation; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D050814:Octamer Transcription Factor-3; C494173:POU5F1 protein, human; D015260:Neprilysin; D002945:Cisplatin